PRRT2 and central nervous system cancer: Conventional PKC (cPKC, including α, β and γ) inhibits LATS kinase activity while novel PKC (nPKC, including δ, θ, ε and η) promotes YAP/TAZ phosphorylation in HEK293A cells, HeLa cells and U251MG glioma cells.